NeoPred, a dual-phase CT AI tool, accurately predicts major pathological response in NSCLC patients preoperatively.
Key Details
- 1NeoPred combines pre-treatment and pre-surgery CT scans with clinical data to predict major pathological response (MPR) in NSCLC undergoing neoadjuvant chemo-immunotherapy.
- 2Study included 509 patients across four oncology centers (459 retrospective, 50 prospective, 59 external validation).
- 3NeoPred reached AUCs of 0.772 (imaging only) and 0.787 (imaging plus clinical data) on external validation, outperforming thoracic surgeons (AUC 0.760 vs 0.720) in prospective testing.
- 4AI support improved surgeons' AUC to 0.829 and diagnostic accuracy to 82%.
- 5NeoPred identified 'pseudo-stable' responders missed by standard RECIST criteria, with AUCs of 0.742 (external) and 0.833 (prospective).
Why It Matters
Accurately predicting response before surgery could enable earlier, evidence-based clinical decisions for NSCLC, reducing overtreatment and personalizing care. This work demonstrates the expanding role and performance advantage of AI-assisted imaging over traditional assessment in complex oncologic management.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.